SBIR-STTR Award

Protectan Cblb502 For The Improvement Of Head And Neck Cancer Radiation Therapy
Award last edited on: 2/11/14

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$200,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Anatoli Gleiberman

Company Information

Cleveland BioLabs Inc (AKA: CBL~Buffalo Biolabs LLC)

73 High Street
Buffalo, NY 14203
   (716) 849-6810
   info@cbiolabs.com
   www.cbiolabs.com
Location: Single
Congr. District: 26
County: Erie

Phase I

Contract Number: N43CO120077
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2012
Phase I Amount
$200,000
Head and neck (H&N) cancer is recognized as a significant threat to public health and a substantial economic challenge. The efficacy of radiotherapy widely used to treat H&N cancer is limited by severe adverse effects, such as mucositis. Currently, there are no drugs effectively preventing these complications. This situation constitutes a significant problem and an outstanding business opportunity for the development of new clinical radioprotectors to improve safety and efficiency of H&N cancer radiation therapy. This Phase I application is focused on exploring applicability of Protectan CBLB502 in minimizing radiation damage to healthy tissues in H&N cancer radiation treatment. The results of preliminary studies published by the investigators of this project provided the first evidence of feasibility of the proposed strategy. The Research Plan includes two specific aims that would (i) demonstrate protective effect of CBLB502 for healthy H&N tissues irradiated under ¿close-to-clinical¿ radiation regimen in mice; and (ii) explore the combination of radiation/CBLB502 treatment for improvement of efficacy and safety of radiotherapy in mouse model of H&N cancer. These milestones will provide a starting point for the Phase II program to complete preclinical studies, open an IND and start a clinical trial in patients with H&N cancers.

NIH Spending Category:
Cancer; Dental/Oral and Craniofacial Disease; Orphan Drug; Rare Diseases

Project Terms:
Adjuvant; Adverse effects; Area; Businesses; cancer radiation therapy; Clinical; Clinical Treatment; Clinical Trials; Development; Dose; Economics; Goals; Head and Neck Cancer; Head and neck structure; improved; irradiation; mouse model; Mucositis; Mus; Oral mucous membrane structure; Patients; Pharmaceutical Preparations; Phase; preclinical study; prevent; programs; protective effect; public health medicine (field); Publishing; Radiation; Radiation therapy; Regimen; Research; Research Personnel; research study; Safety; Series; Squamous cell carcinoma; Therapeutic Index; Tissues; tumor

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----